Jul 2026 $3 M Private placement after listing $2 to $10 million 33
Hepion Pharmaceuticals, Inc.: Private sale, Jul 2026 × Investors in this round 33 investors had bought by the notice of Aug 5, 2026: 33 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Gary Stetz · Executive Officer, Director · Interim Chief Executive Officer Vincent LoPriore · Executive Officer, Director · Executive Chairman Chase LoPriore · Director Dania Fisher · Director Gary S. Stetz, II · Director Michael Purcell · Director Sireesh Appajosyula · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Not applicable. · Unknown Sold in all US states Signed by Gary Stetz, Interim Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 5, 2026. Read the notice at the SEC .
equity, options SEC Jul 2024 $3 M Private placement after listing $2 to $10 million 7
Hepion Pharmaceuticals, Inc.: Private sale, Jul 2024 × Investors in this round 7 investors had bought by the notice of Jul 24, 2024: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, debt Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $175,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John Cavan · Executive Officer · Interim Chief Executive Officer and Chief Financial Officer John P. Brancaccio · Director Kaouthar P. Lbiati · Director Michael P. Purcell · Director Timothy P. Block · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round A.G.P./Alliance Global Partners (CRD 000008361) · Westport, Connecticut Sold in FL, NV, NY, and outside the US Laidlaw & Company (UK) Ltd. (CRD 000119037) · New York, New York Sold in FL, NV, NY, and outside the US Remarks in the notice On fees: “$52,500 of the reported sales commission was paid to A.G.P./Alliance Global Partners and $122,500 of the reported sales commission was paid to Laidlaw & Company (UK) Ltd.”Signed by John Cavan, Interim Chief Executive Officer and Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 24, 2024. Read the notice at the SEC .
equity, debt SEC Sep 2023 $5 M Private placement after listing $2 to $10 million 1
Hepion Pharmaceuticals, Inc.: Private sale, Sep 2023 × Investors in this round 1 investor had bought by the notice of Oct 3, 2023: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $399,996
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John Cavan · Executive Officer · Chief Financial Officer Robert Foster · Executive Officer, Director · Chief Executive Officer and Director Anand Reddi · Director Gary S. Jacob · Director John P. Brancaccio · Director Kaouthar P. Lbiati · Director Petrus P. Wijngaard · Director Timothy P. Block · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round A.G.P./Alliance Global Partners (CRD 8361) · Westport, Connecticut Sold in NY Signed by Robert Foster, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 3, 2023. Read the notice at the SEC .
equity, options SEC Nov 2022 $20 M Private placement after listing $10 to $50 million 8
Hepion Pharmaceuticals, Inc.: Private sale, Nov 2022 × Investors in this round 8 investors had bought by the notice of Nov 15, 2022: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $20 M of $20 M offered
Smallest investment taken no minimum stated
What was sold equity, other: Sale and issuance of Series F preferred stock and Series G preferred stock and the underlying shares of Common Stock issuable upon the conversion thereof Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,000,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice John Cavan · Executive Officer · Chief Financial Officer Robert Foster · Executive Officer, Director · Chief Executive Officer and Director Todd Hobbs · Executive Officer · Chief Medical Officer Arnold P. Lippa · Director Gary S. Jacobs · Director John P. Brancaccio · Director Petrus P. Wijngaard · Director Timothy P. Block · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round A.G.P./ Alliance Global Partners (CRD 8361) · Westport, Connecticut Sold in all US states Signed by Robert Foster, Chief Executive Officer, Director. Source: SEC Form D, newest notice filed Nov 15, 2022. Read the notice at the SEC .
equity SEC Mar 2019 $1 M Private placement after listing Under $2 million 1
Hepion Pharmaceuticals, Inc.: Private sale, Mar 2019 × Investors in this round 1 investor had bought by the notice of Mar 27, 2019: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity, debt Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John P. Cavan · Executive Officer Robert Foster · Executive Officer, Director Arnold P. Lippa · Director Gary S. Jacob · Director John P. Brancaccio · Director Thomas P. Adams · Director Timothy P. Block · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by John Cavan, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 27, 2019. Read the notice at the SEC .
equity, debt SEC Oct 2014 $9 M No. 3 $2 to $10 million 1
Hepion Pharmaceuticals, Inc.: Raise no. 3, Oct 2014 × Investors in this round 1 investor had bought by the notice of Oct 23, 2014: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $9 M of $13 M offered; $4 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Bill Hornung · Executive Officer James Sapirstein · Executive Officer, Director Christopher McGuigan · Director Gary Jacob · Director John Brancaccio · Director Timothy Block · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by James Sapirstein, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 23, 2014. Read the notice at the SEC .
equity SEC Aug 2014 $5 M No. 2 $2 to $10 million 19
Hepion Pharmaceuticals, Inc.: Raise no. 2, Aug 2014 × Investors in this round 19 investors had bought by the notice of Aug 22, 2014: 19 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Bill Hornung · Executive Officer James Sapirstein · Executive Officer, Director Christopher McGuigan · Director Gary Jacob · Director John Brancaccio · Director Timothy Block · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by James Sapirstein, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 22, 2014. Read the notice at the SEC .
equity SEC Feb 2014 $3 M No. 1 $2 to $10 million 19
Hepion Pharmaceuticals, Inc.: Raise no. 1, Feb 2014 × Investors in this round 19 investors had bought by the notice of Feb 14, 2014: 19 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken $25,000
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Bernard F. Denoyer · Executive Officer, Director Gary S. Jacob · Executive Officer, Director Christopher P. McGuigan · Director John P. Brancaccio · Director Timothy P. Block · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds to pay salaries to its officers and directors.”Signed by Gary S. Jacob, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 14, 2014. Read the notice at the SEC .
equity, options SEC